Tags : Jonathan Milner

VAR - Enterprise Software

Clustermarket secures £2.5 million Seed investment from 24Haymarket and Forward

24Haymarket and Forward Partners invest $3.5m in Clustermarket  World’s leading laboratory operating system used by MIT, Oxford and Cambridge universities Lists over 70,000 scientific instruments on its platform and is used by over 60,000 scientists Company is seeing 20% user growth month on month over the past 18 months  24 June, London, Berlin: 24Haymarket, a […]Read More

South East

Sense Biodetection secures £35.86 million Series B investment led by

Sense Raises $50m Series B to Accelerate Launch of COVID-19 molecular test on its Veros™ Instrument-Free Product Platform The investment led by Koch Disruptive Technologies helps Sense accelerate its portfolio of products to deliver patient-focused healthcare April 20, 2021 – Sense Biodetection (Sense), today announced that it has raised a $50m Series B investment to advance […]Read More

East of England

PhoreMost secures £33 million Series B investment led by BGF

PhoreMost closes £33M ($46M) Series B financing Funding to support progression of PLK1 program, for treatment of brain cancer, into the clinic within 18 months Company is advancing its pipeline of novel therapies for oncology and diseases of ageing, and developing novel therapeutic modalities in the targeted protein degradation space Oversubscribed investment round led by BGF, […]Read More

Seed

Pill Connect secures £510k Series A Follow On investment led

Pill Connect secures £0.5m to take electronic smart pill bottle that monitors patient adherence to commercial launch Pill Connect system physically dispenses a pill when patients respond to an app reminder with prompts by text or phone if pill is not dispensed Provides clinicians and trialists with comprehensive data on patient’s adherence pattern Pill Connect, formerly […]Read More

Original

PharmEnable secures £1.8 million Seed investment led by Cambridge Enterprise

Cambridge Spin-out PharmEnable Raises £1.8 million for Drug Discovery Expansion £1.8m seed financing led by Cambridge Enterprise alongside angel investors and life science investment funds Using advanced medicinal chemistry and AI approaches to develop highly complex and specific drug candidate molecules Will enable in-house drug discovery across a number of therapeutic areas including cancer and […]Read More

BioTech

Qkine secures £1.5 million Series A investment led by Parkwalk

Qkine secures £1.5M series A funding from leading life science investors to accelerate global scale-up and make key hires to leadership team Cambridge, UK 08 June 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – today announced the successful closure of a £1.5M series A investment round […]Read More

AI/ML

Healx secures £43.86 million Series B investment led by Atomico

Healx secures $56M in Series B financing, launches global accelerator programme for rare diseases Latest round of funding, led by Atomico, will be used to build a clinical-stage portfolio for rare diseases, including treatments for fragile X syndrome, the leading genetic cause of autism Healx’s Rare Treatment Accelerator programme is a new initiative launched in […]Read More

AI/ML

Healx secures £7.67 million Series A investment led by Balderton

Healx raises $10m as investors back AI to find rare disease treatments faster Viagra inventor and Cambridge graduate use AI to cut medicine development time by 80% Cambridge, UK – 26th July, 2018 – Healx (https://healx.io), the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, today announced a $10 million Series A funding round, […]Read More